ArticleJournal of neurology2009
Radiological progression of cerebral metastases after radiosurgery: assessment of perfusion MRI for differentiating between necrosis and recurrence.
Article in Journal of neurology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 3 syntheses or guidelines pooled it, 169 citations in OpenAlex.
- Dynamic susceptibility MR perfusion in diagnosing recurrent brain metastases after radiotherapy: A systematic review and meta-analysis.Journal of magnetic resonance imaging : JMRI · 2020Pooled it
- Perfusion MRI as a diagnostic biomarker for differentiating glioma from brain metastasis: a systematic review and meta-analysis.European radiology · 2018Pooled it
- Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery.The Cochrane database of systematic reviews · 2018Pooled it
- Intraoperative radiotherapy after resection of newly diagnosed brain metastases in adult patients - results of a prospective phase II trial (INTRAMET).Journal of neuro-oncology · 2026Trial
- Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance.Neuro-oncology · 2024Trial
- Detectability of radiation-induced changes in magnetic resonance biomarkers following stereotactic radiosurgery: A pilot study.PloS one · 2018Trial
- Pathology-validated structural and physiologic habitat imaging for differentiating radiation necrosis from tumor recurrence in brain metastases.Journal of neuro-oncology · 2026Article
- Imaging MRI biomarkers for diagnosing brain radionecrosis: focus on incomplete ring enhancement sign.Neuroradiology · 2026Article
- Nodular Meningeal Recurrence After Laser Interstitial Thermal Therapy for Brain Metastasis: Diagnostic Challenges and Role of Reirradiation With Preoperative Fractionated Stereotactic Radiation Therapy.Advances in radiation oncology · 2026Article
- Percentage signal recovery plus relative cerebral blood volume: a practical dual-parameter strategy for differentiating post-stereotactic radiosurgery tumour progression from radiation necrosis in brain metastases.Insights into imaging · 2026Article
- Auxiliary Value of [Cancers · 2025Article
- Histopathologically confirmed radiation necrosis: Risk factors and clinical outcomes in patients with primary brain tumors.Neuro-oncology practice · 2025Article
- Predictive value of early DCE and DSC perfusion MRI parameters for midterm clinical outcomes in lung cancer brain metastases treated with stereotactic radiosurgery.Journal of neuro-oncology · 2025Article
- Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care.Nature reviews. Clinical oncology · 2025Review
- A Combined Approach Using T2*-Weighted Dynamic Susceptibility Contrast MRI Perfusion Parameters and Radiomics to Differentiate Between Radionecrosis and Glioma Progression: A Proof-of-Concept Study.Life (Basel, Switzerland) · 2025Article
- Long-Term Imaging Follow-up of Radiation Necrosis After Stereotactic Radiosurgery: A Case Report and Lessons Learned.Advances in radiation oncology · 2024Article
- Diagnostic Utility of Integration of Dynamic Contrast-Enhanced and Dynamic Susceptibility Contrast MR Perfusion Employing Split Bolus Technique in Differentiating High-Grade Glioma.The Indian journal of radiology & imaging · 2024Article
- Evaluating the Efficacy of Perfusion MRI and Conventional MRI in Distinguishing Recurrent Cerebral Metastasis from Brain Radiation Necrosis.Brain sciences · 2024Article
- Tumor Habitat Analysis Using Longitudinal Physiological MRI to Predict Tumor Recurrence After Stereotactic Radiosurgery for Brain Metastasis.Korean journal of radiology · 2023Article
- DSC Perfusion MRI-Derived Fractional Tumor Burden and Relative CBV Differentiate Tumor Progression and Radiation Necrosis in Brain Metastases Treated with Stereotactic Radiosurgery.AJNR. American journal of neuroradiology · 2022Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To assess the capability of perfusion MRI to differentiate between necrosis and tumor recurrence in patients showing radiological progression of cerebral metastases treated with stereotactic radiosurgery (SRS). From 2004 to 2006 dynamic susceptibility-weighted contrast-enhanced perfusion MRI scans were performed on patients with cerebral metastasis showing radiological progression after SRS during follow-up. Several perfusion MRI characteristics were examined: a subjective visual score of the relative cerebral blood volume (rCBV) map and quantitative rCBV measurements of the contrast-enhanced areas of maximal perfusion. For a total of 34 lesions in 31 patients a perfusion MRI was performed. Diagnoses were based on histology, definite radiological decrease or a combination of radiological and clinical follow-up. The diagnosis of tumor recurrence was obtained in 20 of 34 lesions, and tumor necrosis in 14 of 34. Regression analyses for all measures proved statistically significant (chi(2) = 11.6-21.6, P < 0.001-0.0001). Visual inspection of the rCBV map yielded a sensitivity and specificity of 70.0 respectively 92.9%. The optimal cutoff point for maximal tumor rCBV relative to white matter was 2.00 (improving the sensibility to 85.0%) and 1.85 relative to grey matter (GM), improving the specificity to 100%, with a corresponding sensitivity of 70.0%. Perfusion MRI seems to be a useful tool in the differentiation of necrosis and tumor recurrence after SRS. For the patients displaying a rCBV-GM greater than 1.85, the diagnosis of necrosis was excluded. Salvage treatment can be initiated for these patients in an attempt to prolong survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.